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Conclusion: For the small lesions with a volume smaller than 
4 cm³ the Agility shows a steeper gradient in the two 
surrounding rings than the MLCi1. Therefore we recommend 
the use of the Agility for treating the smaller lesions.  
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Purpose or Objective: To obtain a planning technique for 
SBRT treatment of multiple lung tumors, which is suitable for 
all relative positions of the tumors. 
 
Material and Methods: For 10 patients with two tumors, 
treated with 3 x 18Gy, VMAT plans were generated in 
Pinnacle, using various approaches: simultaneous versus 
sequential optimization, with or without the dose distribution 
of one tumor as background for optimization of the other 
tumor. The quality of the treatment plans was judged on 
coverage (PTV V100% >95%), conformity (V100%/PTV volume), 
inhomogeneity (PTV D0<165%) and dose constraints on OARs.  
 
Results: Simple addition of beams for two independently 
planned tumors does not yield optimal results since the 
mutual low dose contributions cannot be taken into account 
properly. Simultaneous optimization on both targets results 
in pairs of open leafs in-between the lesions (Fig 1). We 
therefore concluded that the strategy that yields the most 
conformal plans is the subsequent planning of the tumors 
using a dual-arc for both, where the dose distribution 
resulting from the planning of the first target is used as a 
background dose while optimizing the beams for the second 
target. During optimization of the first tumor, no limit is 
applied for the dose to the second PTV, since this can be 
compensated for in the optimization procedure for this PTV. 
After optimization of the second PTV, the number of monitor 
units in each beam pair might be adjusted slightly to conform 
to the required target coverage. This strategy works for two 
or more isocenters as well as for one mutual isocenter. For 
three or more tumors, iterating the above method yields 
good results 
 
 
Conclusion: We developed a generic planning strategy to 
obtain high quality lung SBRT-treatment plans for patients 
with multiple lung tumors. The strategy uses a dual-arc VMAT 
for each tumor, while taking the dose distribution covering 
the first target is used as background during dose 
optimization for the second target. This method is clinically 
in use since March 2015, since then 15 patients have been 
treated using this method. 
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Purpose or Objective: Two centers compared 
VMAT/RapidArc (RA) and Tomotherapy (TOMO). for the 
irradiation of breast and regional lymph nodes. 
 
Material and Methods: Five left and five right breasts plus 
regional nodes have been contoured by two dedicated 
radiation oncologists. Two senior physicists checked the 
treatment plans studied by dedicated dosimetrists. The 
Anatom-e tool was tested for improving definition and 
avoiding interpersonal variability in the contouring. 
Prescription, according to ICRU, was 50 Gy in 25 daily 
fractions. We considered both lungs, the heart, the left 
anterior descending coronary artery (LAD), the controlateral 
breast and the thyroid as Organa t Risk (OaR). The dose 
constraints were: PTV V95=95%, ipsilateral lung V20 ≤20%, 
heart mean dose < 10Gy, heart max dose <35Gy, LAD max 
dose ≤20Gy, thyroid max dose < 45 Gy and contralateral 
breast max dose≤5 Gy. We have studied the treatments in 
free breathing modality, perfectly aware of the higher dose 
received by heart and LAD in comparison to the respiratory- 
gated modality, routinely used in the RA center. 
 
Results: We summarized the results of this comparison in 
Table 1  
Table 1. Left and right breast plus lymphnodes. 
 
 
 
Conclusion: Both techniques allow a good coverage and dose 
uniformity for the PTV, with proper sparing of the OaR. TOMO 
